

Supplementary Table and Figures


Supplementary Table S1. Synthetic 517 bp DNAs and primers used to generate Survivin (SVN) derived immunogens.

Survivin (SVN) derived immunogens	DNA sequences
WT-Full SVN	ACAGGCTGTCGCCGTGCTCATTGATCCATGGTGTATATTACTGTGCGATGGGAGCACCAGCACTACCACAAATATGGCAAC TATACCTAAAAAATACCGAATAGCAACATTCAAAAACTGGCCATTCTAGAAAGACTGCGCATGCACACCAGAACGAATGGC AGAAGCAGGATTCATACACTGCCCAACAGAAAAACGAACCAGACCTAGCACAATGCTTCTTCTGCTTCAAAGAACTAGAAGGA TGGGAACCAGACGACAACCCAATAGAAGAACCAGAAAACTCACCAGGATGCGCATTCTAACAGTAAAAAACAATG GAAGAATAACAGTATCAGAATTCCTAAAACTAGACGACAACGAGCAAAAAACAATAAGCAAAAGAAACAACAACAAC AAAAAGAATTCGAAGAAACAGCAAAAAACAACGACAATCAATAGAACAACACTAGCAGCATGGGGCCAGGGAACCTAGGGAT CCATCAGAAGGGATCTTGTGCCGCC
VEL-Full SVN	ACAGGCTGTCGCCGTGCTCATTGATCCATGGTGTATATTACTGTGCGATGGGAGCACCANNKCTACCACAAATATGGCAAC TATACCTANNKAACACTANNKATAGCANNKTTCAAAAACTGGCCATTCTANNKGACNNKGCANNKACACCANNKCGAATGGC AGAAGCAGGATTCATACACTGCCCAACAGAAAAACGAACCAGACCTAGCACAANNKTTCTTCTGCTTANNKGAAC TAGAAGGA TGGNNKCCANNKGACNNKCCAATAGAAGAAANNKCGAAAACTCACCAGGATGCGCATTNNKACANNKAAANNKCAAATG GAANNKCTAACANNKTCANNKTTCTAAAACTANNKCGACAANNKGCAAAAACAANNKGCAAAAGAAACAACAACAAC AAAAANNKTTGAAGAAACAGCANNKACAACACGACAATCAATAGAACAACACTAGCAGCATGGGGCCAGGGAACCTAGGGAT CCATCAGAAGGGATCTTGTGCCGCC
	Primers (Oligonucleotides)*
WT-Full SVN VEL-Full SVN	5SF: TATTCGTCTGCAGGACCATGGTGTATATTACTGTGCGATG 3SNT: TACTTATCTAGAGGATCCCTAGGTGACCGTCTTGCCATTCG
WT-NT VEL-NT	5SF: TATTCGTCTGCAGGACCATGGTGTATATTACTGTGCGATG 3SFX: ATACGTTCTAGAGGATCCCTAGGTTCCTTGCC
WT-Core VEL-Core	5SM: GCTATCCTGCAGGACCATGGAGCAGGATTCATACACTGC 3SM: TATATTGTCTAGAGGATCCCTAGGTGACCACTTCCATTTG
WT-CT VEL-CT	5SCT: TTACATGCTGCAGTACCATGGTCAAATGGAA 3SNT: TACTTATCTAGAGGATCCCTAGGTGACCGTCTTGCCATTCG

NNK: where **N**= G, A, T or C and **K**= G or T.

*Oligonucleotide (oligos) pairs carrying Nco I and Bam HI restriction sites (underlined in oligos).


Supplementary Figure S1



Supplementary Figure S1. Representative flow cytometric analysis of CD4⁺ and CD8⁺ T cell proliferation, derived from spleen cells using CFSE.

This figure shows the staining of CD4⁺ and CD8⁺ spleen cells with CFSE, histograms for controls are also shown: positive for proliferation using concanavalin A (ConA), negative for proliferation (without stimulation) and a stimulus with an individual variant antigen displayed on phage.


Supplementary Figure S2



Supplementary Figure S2. Representative flow cytometric analysis of CD8⁺Ly6C⁺ effector T cell phenotyping from lung tissue samples.

Figure represents CD8⁺Ly6C⁺ effector T cells. The following gating strategy was applied to obtain results: cells separated into double singlets; identification of live CD3⁺ cells; identification of CD8⁺ and CD4⁺ from previous; and finally, identification of effector CD8⁺Ly6C⁺ T cells. Representative dot plot graphs shown for treatments with VEL-NT, WT-NT, VEL-CT, WT-CT, Untreated, U.E. and naive mice.


Supplementary Figure S3



Supplementary Figure S3. Representative flow cytometric analysis of CD11b⁺Ly6C^{int/low}Ly6G⁺ granulocytic myeloid-derived suppressor cells (G-MDSCs) phenotyping from tumor tissue sample.

Figure represents gating strategy used to identify G-MDSC cells. Separation of cells into double singlets; identification of live CD11b⁺ cells; and finally, identification of CD11b⁺Ly6C^{int/low}Ly6G⁺ cells. Representative dot plot graphs shown for treatments with VEL-NT, WT-NT, VEL-CT, WT-CT, Untreated, U.E.


Supplementary Figure S4



Supplementary Figure S4. Representative flow cytometric analysis of CD4⁺CD25⁺FoxP3⁺ regulatory T cells (T_{regs}) phenotyping from lung tissue sample.

Figure represents strategy used to identify T_{reg} cells. Separation of cells into double singlets; identification of live CD3⁺CD4⁺ cells; and finally, identification of CD4⁺CD25⁺FoxP3⁺ cells. Representative dot plot graphs are shown for treatments with VEL-NT, WT-NT, VEL-CT, WT-CT, Untreated, Naive mice and Fluorescence Minus One (FMO) Control for FoxP3.

Supplementary Figure S5



Supplementary Figure S5. The phenotyping of Memory T cells.

We measured by multiparametric flow-cytometry *ex-vivo* the presence of central memory and effector memory CD8⁺ and CD4⁺ T cells within the spleens, showing significantly higher level of effector memory T cells in mice immunized with VEL-NT **(A)** or VEL-CT **(B)** at day 90 after vaccination. Percentages of T cells (%) are presented as mean \pm 95 CI and were analyzed with two-way ANOVA for repeated measurements and Sidak “post-hoc” test for multiple comparisons (* $P < 0.033$, ** $P < 0.02$, *** $P < 0.001$).